Synthego, a US-based genome engineering technology developer backed by life sciences real estate developer Alexandria Real Estate Equities, has secured $110m in a series C round.
Founders Fund led the round, which also featured fellow venture capital firms 8VC and Menlo Ventures, increasing Synthego’s overall funding to $160m.
Founded in 2012, Synthego has created a genome engineering platform for use in the development of cell and gene therapies.
The platform utilises automation, bioinformatics, and machine learning technology, and allows researchers to get engineered cells with edits in a specific target with just one click. Synthego will use the funding for product development, enhancing its Engineered Cells and Crisprevolution lines, while expanding in Europe and Asia.
Paul Dabrowski, Synthego’s co-founder and chief executive, said: “This new funding allows us to expand our reach and build out our full stack platform capabilities at a perfect time.
“Biological medicines are on the cusp of a revolution with the coming curative cell and gene therapies, and we are proud to support this industry.”
The company raised $8.3m in 2013 before Alexandria Real Estate Equities, 8VC, AME Cloud Ventures, Elements Capital, OS Fund, ZhenFund, Jennifer Doudna and Jamie Doudna Cate joined existing backers Founders Fund, Menlo Ventures, WI Harper and SciFi VC for a $41m series B in January 2017.
